Voyager Therapeutics (NASDAQ:VYGR) Earns Buy Rating from HC Wainwright

Key Points

• HC Wainwright reaffirmed its “Buy” rating on Voyager Therapeutics, while analyst coverage overall indicates a “Moderate Buy” consensus and a $16.50 price target.
• Voyager reported quarterly adjusted losses of $0.40 per share, beating estimates of $0.48, but revenue of $3.17 million fell short of the $4.52 million consensus estimate.
• The stock opened at $3.27, with a market capitalization of approximately $197.6 million; institutional investors own 48.03% of outstanding shares.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report)'s stock had its "buy" rating reaffirmed by stock analysts at HC Wainwright in a research note issued to investors on Monday,Benzinga reports.

VYGR has been the topic of a number of other research reports. Weiss Ratings reissued a "sell (d-)" rating on shares of Voyager Therapeutics in a report on Monday, July 13th. Wall Street Zen lowered shares of Voyager Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, May 9th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Voyager Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $16.50.

Voyager Therapeutics Stock Performance

Voyager Therapeutics stock opened at $3.27 on Monday. The stock has a market cap of $197.57 million, a P/E ratio of -1.82 and a beta of 1.31. The firm's fifty day moving average price is $3.40 and its 200-day moving average price is $3.73. Voyager Therapeutics has a fifty-two week low of $2.93 and a fifty-two week high of $5.55.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.40) earnings per share for the quarter, beating analysts' consensus estimates of ($0.48) by $0.08. The company had revenue of $3.17 million for the quarter, compared to analysts' expectations of $4.52 million. Voyager Therapeutics had a negative return on equity of 54.82% and a negative net margin of 312.63%. On average, analysts predict that Voyager Therapeutics will post -1.43 earnings per share for the current year.

Institutional Trading of Voyager Therapeutics

A number of large investors have recently made changes to their positions in the stock. Altshuler Shaham Ltd purchased a new position in Voyager Therapeutics in the fourth quarter worth about $801,000. EcoR1 Capital LLC increased its holdings in shares of Voyager Therapeutics by 497.2% in the 4th quarter. EcoR1 Capital LLC now owns 4,002,847 shares of the company's stock worth $15,731,000 after buying an additional 3,332,544 shares during the last quarter. Renaissance Technologies LLC boosted its stake in shares of Voyager Therapeutics by 95.0% during the 1st quarter. Renaissance Technologies LLC now owns 578,024 shares of the company's stock worth $2,231,000 after purchasing an additional 281,574 shares during the period. Sei Investments Co. purchased a new stake in shares of Voyager Therapeutics in the first quarter worth approximately $112,000. Finally, Chase Investment Counsel Corp bought a new position in Voyager Therapeutics in the first quarter worth approximately $76,000. 48.03% of the stock is currently owned by institutional investors.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company's core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm's pipeline includes several AAV-based candidates in preclinical and early clinical development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source